Drug doesn't significantly lower risk of major heart problems in dialysis patients

In one of the largest and longest trials involving patients with kidney failure, a study led by an international team of researchers found that cinacalcet -- a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism -- does not significantly reduce the risk of death or major cardiovascular events.

Read the whole article on Science Daily

More from Science Daily